Somatic mutations in EGFR and K-ras are mutually exclusive in NSCLC [17], which has led investigators to hypothesize that these events are genetically redundant and that a change in both genes does not confer a further advantage when these events occur together in the same cell [17]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.